ClinicalTrials.gg
CompletedNCT05537090Updated Nov 21, 2023

A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants

A Phase 1 interventional study of BV100 and Midazolam in Healthy Volunteers, sponsored by BioVersys AG. Completed at 1 site in Hungary. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by BioVersys AG · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To evaluate the effect of repeated doses of intravenous BV100 on the pharma-cokinetics of midazolam and 1-hydroxymidazolam.

Read the detailed description

A single center, open-label, 3-period fixed-sequence, Phase I clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Midazolam and its metabolite 1-hydroxymidazolam in healthy volunteers

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

BioVersys AG is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who were able to understand and follow instructions during the study.
  2. Subjects who signed .
  3. Male subjects ≥18 and ≤55 years of age; female subjects ≥18 and ≤55 years of age of nonchildbearing potential defined as follows:

    • Female subjects 50 years of age or older, in menopause for 24 con-secutive months and not receiving any hormone replacement therapy within 24 months prior to inclusion into the study
    • Female subjects who underwent surgical sterilization
    • Female subjects who underwent hysterectomy
    • Female subjects with documented premature ovarian failure
  4. Weight within a range of 19.0-30.0 kg/m2.
  5. Estimated (eGFR) according to the CKD-EPI: ≥90 mL/min (normal renal function)
  6. Healthy subjects had to be in a good health in the opinion of the study phy-sician, as determined by medical history, , vital signs, physical examina-tion, and clinical laboratory tests.
  7. Having had no febrile or infectious illness for at least 14 days prior to dos-ing.
  8. The subject was available to complete the study.
  9. The subject was complying with the restrictions and requirements of the protocol and, in the opinion of the study physician, was able to complete the study.

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or unable to give .
  2. As a result of the medical screening process, the study physician considered the subject unfit for the study.
  3. Pregnant or lactating women or men with female partners who are lactating or are pregnant.
  4. Known or suspected history of to rifabutin or or to drugs of a similar chemical class including rifampicin, rifapentine, rifaximin; history of allergic reactions leading to hospitalisation or any other allergic con-ditions (including drug allergies, asthma, eczema, anaphylactic reactions but excluding untreated, asymptomatic, seasonal allergies) which the Investigator considers may affect the safety of the subject and/or outcome of the study.
  5. History of antibiotic associated diarrhoea within the last year.
  6. Volunteers with abnormalities (history, or evidence of second-degree heart block of Mobitz type II, third degree heart block, or any abnormality con-sidered relevant by the Investigator), > 450 ms, PR > 200 ms, or QRS duration > 110 ms.
  7. Supine systolic blood pressure > 140 mmHg or \< 90 mmHg or diastolic blood pressure > 90 mmHg or \< 50 mmHg at Screening or Day 1 prior to dos-ing (any abnormal blood pressure results may be repeated once and if the re-peat result is within the normal range, it is not considered to have met the ex-clusion criterion). Pulse rate > 90 or \< 50 beats per minute at Screening or Day 1 prior to dosing.
  8. (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and creatinine, above the at Screening. Any abnor-mal value of these parameters may be repeated during screening period and if the repeat result is within the laboratory reference range, it is not considered to have met the exclusion criterion.
  9. Screening values other than AST, ALT, ALP, creatinine, for haematology, biochemistry, or urinalysis must not exceed the reference range. Minor devia-tions from normal are allowed, if they are not .
  10. Leucocytes or neutrophils or lymphocytes below the lower limit of the ref-erence range.

11 History of symptomatic, chronic or recurrent infection (e.g. nausea, vomit-ing, diarrhoea, infection with fever) or any viral (including symptomatic herpes zoster), bacterial (including upper respiratory infection), fungal (non-cutaneous) or parasitic infection within 30 days prior to admission to the clini-cal unit.

  1. A positive pre-study serology test for surface antigen (HBsAg), virus (HCV) antibodies or (HIV)-1 and/or 2 antibodies.
  1. Positive Coronavirus (SARS-CoV-2) rapid test and PCR (upon Check-in on Day -1) 14. A positive pre-study drug/alcohol screen. 15. History of epilepsy, other neurological disorders, or neuropsychiatric con-ditions.
  1. History of seizures. 17. Volunteers who have received any prescribed systemic or topical medica-tion within 4 weeks of the first dose administration.
  1. Subjects who had used any non-prescribed systemic or topical medication (including herbal remedies) or megadose vitamins (i.e. 20 to 600 times the rec-ommended daily supplement dose) within 7 days prior to dosing, unless in the opinion of the study physician the medication did not interfere with the study procedures or compromise safety.
  1. Volunteers who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration.
  1. Regular use of any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to the first admission to the clinical unit.
  1. Volunteers who have participated in a clinical study involving administra-tion of an drug (new chemical entity) within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (which-ever is longer).
  1. Volunteers who consume more than 21 units of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse (one unit of alcohol equals ½ pint [285 mL] of beer or lager, one glass [125 mL] of wine, or 30 mL of 40% of alcohol by volume distilled spirits).
  1. Excessive consumption of caffeine- or xanthine-containing food or bever-ages (> 5 cups of coffee a day or equivalent) or inability to stop consuming from 48 hours prior to study treatment administration.
  1. Subjects who smoked more than 10 cigarettes a day. 25. Any use of drugs-of-abuse or alcohol abuse within 2 years prior to the first admission to the clinical unit.
  1. Inability to understand or communicate reliably with the Investigator or considered by the Investigator to be unable to or unlikely to co-operate with the requirements of the study.
  1. Any other conditions or factors which in the opinion of the Investigator may interfere with study conduct. Failure to satisfy the Investigator of fitness to participate for any other reason.
  1. Any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days, or donated plasma within 7 days prior to the first admission to the clinical unit.
  1. Inability to refrain from using soft contact lenses starting from administra-tion of study treatment until follow-up visit.
  1. Volunteers who are study site employees or immediate family members of the study site or Sponsor employee.
  1. related to midazolam: Hypersensitivity to the active sub-stance(s) or to any of the excipients, Severe hepatic impairment, Severe res-piratory failure or acute respiratory depression, Myasthenia gravis, Sleep ap-nea, Anatomical respiratory impairment or lung diseases. Note: as per Midazo-lam smpc "Pharmacokinetic interactions with inhibitors or inducers are more pronounced for oral as compared to oromucosal or parenteral midazo-lam as CYP3A4 enzymes are also present in the upper gastrointestinal tract. Hence, a careful monitoring of the clinical effects and vital signs is recom-mended during the use of midazolam with a CYP3A4 inhibitor even after a single dose".
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    BV100 Plus Midazolam

    A total 2 doses of midazolam and 9 doses of BV100 will be administered to each participant per specified dosing schedule

    Drug: BV100 · Drug: Midazolam

Interventions

  • DrugBV100

    Rifabutin for Infusion

  • Syrup for oral administration

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of midazolam

    Maximum Observed Plasma Concentration (Cmax) of Midazolam

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7

  2. To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of midazolam

    Area Under the Plasma Concentration-Time Curve (AUC) of Midazolam

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7

  3. To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of 1-hydroxymidazolam

    Maximum Observed Plasma Concentration (Cmax) of 1-hydroxymidazolam

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7

  4. To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of 1-hydroxymidazolam

    Area Under the Plasma Concentration-Time Curve (AUC) of 1-hydroxymidazolam

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7

Secondary outcomes

  1. To evaluate the safety, and tolerability in healthy volunteers receiving multiple intravenous doses of BV100 with and without midazolam

    Number of Participants with Treatment-Emergent Adverse Events

    Time frame: 26 days

07

Study locations

1 site
  • CRU Hungary Kft., Early Phase Unit
    Kistarcsa, H-2143, Hungary
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Jul 2023, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2022
First posted
Sep 13, 2022
StartActual
Sep 1, 2022
Primary completionActual
Jul 31, 2023
CompletionActual
Sep 30, 2023
Last update
Nov 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05537090
Lead sponsor
BioVersys AG
Collaborators
CRU Hungary Kft
Responsible party
Sponsor
First posted
Sep 13, 2022
Start date
Sep 1, 2022
Primary completion
Jul 31, 2023
Completion
Sep 30, 2023
Last update
Nov 21, 2023

Study contacts

Geza Lakner
principal investigator · CRU Hungary Kft

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BV100

Start the discussion